Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Liraglutide: Phase III data

In the double-blind Phase III LEAD-3 trial in 746 patients, both doses of liraglutide

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE